A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

Eitemau Tebyg

• A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
  gan: Park, Cheol-Kyu, et al.
  Cyhoeddwyd: (2019)
• Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report
  gan: Park, Cheol Kyu, et al.
  Cyhoeddwyd: (2017)
• Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report
  gan: Li, Jie, et al.
  Cyhoeddwyd: (2020)
• Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
  gan: Park, Mi-Young, et al.
  Cyhoeddwyd: (2017)
• Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
  gan: Yoon, Seong-Hoon, et al.
  Cyhoeddwyd: (2015)